Source:http://linkedlifedata.com/resource/pubmed/id/16621103
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
2006-7-3
|
| pubmed:abstractText |
The alphavirus Venezuelan equine encephalitis virus (VEEV) is highly infectious by the airborne route. It is a hazard to laboratory workers, has been developed as a biological weapon and is a potential bioterrorist agent. A suitable vaccine appears in an advanced stage of development but there remains a need for antiviral drugs, effective in prophylaxis of disease prior to or a short time after exposure to airborne virus. Using a murine model to study monoclonal antibody (MAB) a VEEV complex-specific, glycoprotein E2-binding MAB was identified, able to protect against disease induced by exposure to aerosolised VEEV from serogroups I, II and IIIA (mouse-virulent strains). There was no synergy in protection between anti-E1 and anti-E2 MAB. Assays of MAB virus neutralising activity in a homologous (mouse fibroblast) cell line suggested that neutralisation played a significant role in protection in addition to the previously reported mechanism of Fc receptor-binding [Mathews et al., 1985. J. Virol. 55, 594-600]. Development of an analogous human MAB with identical VEEV epitope specificity may be informed and monitored by reference to these properties.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0168-1702
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
120
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
107-12
|
| pubmed:meshHeading |
pubmed-meshheading:16621103-Animals,
pubmed-meshheading:16621103-Antibodies, Monoclonal,
pubmed-meshheading:16621103-Antibodies, Viral,
pubmed-meshheading:16621103-Antibody Specificity,
pubmed-meshheading:16621103-Bioterrorism,
pubmed-meshheading:16621103-Cells, Cultured,
pubmed-meshheading:16621103-Drug Administration Schedule,
pubmed-meshheading:16621103-Drug Evaluation, Preclinical,
pubmed-meshheading:16621103-Encephalitis Virus, Venezuelan Equine,
pubmed-meshheading:16621103-Encephalomyelitis, Venezuelan Equine,
pubmed-meshheading:16621103-Fibroblasts,
pubmed-meshheading:16621103-Immunization, Passive,
pubmed-meshheading:16621103-Injections, Intraperitoneal,
pubmed-meshheading:16621103-Mice,
pubmed-meshheading:16621103-Mice, Inbred BALB C,
pubmed-meshheading:16621103-Neutralization Tests,
pubmed-meshheading:16621103-Viral Envelope Proteins
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III.
|
| pubmed:affiliation |
Biomedical Sciences, Dstl, Porton Down, Salisbury SP4 0JQ, UK. bjphillpotts@dstl.gov.uk
|
| pubmed:publicationType |
Journal Article
|